During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple ...
How to Select First-Line Immunotherapy for Metastatic NSCLC: PD-L1, Disease Burden, and Co-Mutations
Matthew Gubens, MD, MS, explains how PD-L1 expression, disease burden, and co-mutations guide first-line immunotherapy selection in metastatic non–small cell lung cancer. Selecting first-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results